ARCHIVES

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 17 | May 2, 2008

Download PDF Visit The Full Archive

Related Articles

NCI to Fund 122 More Grants in FY04

March 28, 2003

In Brief: NCI Grants Up Fourfold Since 1970; Rappaport, Jensen Speakers At Annual AACR,ASCO Meeting

April 25, 1975

Lasker Official Urges Congressional Support Of NCI Bypass Budget

April 20, 1990

Doubling Budget For NSF High Priority For FASEB.

April 20, 2001

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

December 10, 2004

House and Senate Appropriators Pledge to Increase Biomedical Research Funding.

March 5, 1999